$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

$rigl Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914001756 Filed on March 04, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013
Revenue	$0.00	$5.750M	$7.200M
YoY Change			213.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.520M	$4.650M	$19.60M
YoY Change	2.22%	-20.51%	-14.04%
% of Gross Profit
Research & Development	$16.87M	$18.05M	$75.33M
YoY Change	-16.96%	-8.65%	-4.38%
% of Gross Profit
Depreciation & Amortization	$655.0K	$650.0K	$2.592M
YoY Change	-2.09%	3.17%	6.54%
% of Gross Profit
Operating Expenses	$16.87M	$22.69M	$75.33M
YoY Change	-16.96%	-11.44%	-4.38%
Operating Profit	-$22.39M		-$89.47M
YoY Change	-12.93%		-9.97%
Interest Expense	$80.00K	$80.00K	$400.0K
YoY Change	-42.86%	-42.86%	-20.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$22.30M	-$16.86M	-$89.00M
YoY Change	-12.79%	-33.8%	-9.92%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.30M	-$16.86M	-$89.00M
YoY Change	-12.79%	-33.8%	-9.92%
Net Earnings / Revenue		-293.22%	-1236.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$254.8K	-$192.8K	-$1.019M
COMMON SHARES
Basic Shares Outstanding	87.52M shares	87.43M shares	87.29M shares
Diluted Shares Outstanding			87.29M shares

Balance Sheet

Concept	2014 Q1	2013 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$195.4M	$212.0M	$212.0M
YoY Change	-28.29%	-28.92%	-28.91%
Cash & Equivalents	$14.91M	$20.85M	$20.90M
Short-Term Investments	$180.5M	$191.1M	$191.1M
Other Short-Term Assets	$2.400M	$2.400M	$2.400M
YoY Change	-20.0%	-42.86%	-42.86%
Inventory
Prepaid Expenses
Receivables	$0.00	$5.750M	$5.800M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$197.8M	$220.1M	$220.1M
YoY Change	-28.17%	-27.24%	-27.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.978M	$4.455M	$4.500M
YoY Change	-31.8%	-23.53%	-22.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.484M	$1.528M	$1.500M
YoY Change	-12.76%	-13.13%	-16.67%
Total Long-Term Assets	$5.462M	$5.983M	$6.000M
YoY Change	-27.12%	-21.12%	-20.0%
TOTAL ASSETS
Total Short-Term Assets	$197.8M	$220.1M	$220.1M
Total Long-Term Assets	$5.462M	$5.983M	$6.000M
Total Assets	$203.3M	$226.1M	$226.1M
YoY Change	-28.14%	-27.09%	-27.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.157M	$3.903M	$3.900M
YoY Change	-45.88%	129.99%	129.41%
Accrued Expenses	$5.400M	$5.200M	$5.200M
YoY Change	-12.9%	-46.94%	-46.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.865M	$10.29M	$10.30M
YoY Change	-14.12%	-15.65%	-15.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$69.00K	$74.00K	$7.500M
YoY Change	-24.18%	-22.92%	-13.79%
Total Long-Term Liabilities	$69.00K	$74.00K	$7.500M
YoY Change	-24.18%	-22.92%	-13.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.865M	$10.29M	$10.30M
Total Long-Term Liabilities	$69.00K	$74.00K	$7.500M
Total Liabilities	$7.934M	$10.37M	$17.80M
YoY Change	-14.22%	-15.71%	-14.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$871.6M	-$849.3M
YoY Change	10.91%	11.71%
Common Stock	$1.060B	$1.057B
YoY Change	0.84%	0.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$188.3M	$208.3M	$208.3M
YoY Change
Total Liabilities & Shareholders Equity	$203.3M	$226.1M	$226.1M
YoY Change	-28.15%	-27.09%	-27.06%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013
OPERATING ACTIVITIES
Net Income	-$22.30M	-$16.86M	-$89.00M
YoY Change	-12.79%	-33.8%	-9.92%
Depreciation, Depletion And Amortization	$655.0K	$650.0K	$2.592M
YoY Change	-2.09%	3.17%	6.54%
Cash From Operating Activities	-$16.43M	-$18.90M	-$86.08M
YoY Change	-34.57%	-12.38%	1.02%
INVESTING ACTIVITIES
Capital Expenditures	$178.0K	-$170.0K	$1.221M
YoY Change	-73.67%	-71.67%	-63.84%
Acquisitions
YoY Change
Other Investing Activities	$10.64M	$23.67M	$73.62M
YoY Change	-59.79%	-121.98%	-306.45%
Cash From Investing Activities	$10.46M	$23.50M	$72.40M
YoY Change	-59.44%	-121.7%	-285.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.00K		$1.051M
YoY Change			-99.24%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	230.0K	1.050M
YoY Change		-99.83%	-99.25%
NET CHANGE
Cash From Operating Activities	-16.43M	-18.90M	-86.08M
Cash From Investing Activities	10.46M	23.50M	72.40M
Cash From Financing Activities	20.00K	230.0K	1.050M
Net Change In Cash	-5.950M	4.830M	-12.63M
YoY Change	-975.0%	-27.69%	-185.05%
FREE CASH FLOW
Cash From Operating Activities	-$16.43M	-$18.90M	-$86.08M
Capital Expenditures	$178.0K	-$170.0K	$1.221M
Free Cash Flow	-$16.61M	-$18.73M	-$87.30M
YoY Change	-35.59%	-10.68%	-1.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	249000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	452000	USD
CY2012Q4	rigl	Unrecognized Tax Benefits That Would Impact Other Tax Accounts Including Deferred Taxes UnrecognizedTaxBenefitsThatWouldImpactOtherTaxAccountsIncludingDeferredTaxes	3300000	USD
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2350000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	302458000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1759000	USD
CY2013Q4	us-gaap	Assets Assets	226058000	USD
CY2012Q4	us-gaap	Assets Assets	310043000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3903000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2849000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6775000	USD
CY2013Q4	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	1588000	USD
CY2012Q4	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	2124000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	746000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	942000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	274054000	USD
CY2013Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	202721000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-849274000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1208000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	666000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10294000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12204000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7439000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8647000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	88000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	87000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1057390000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1049174000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	47000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760247000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	208251000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	289096000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226058000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310043000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013	rigl	Share Based Compensation Number Of Stock Option Plans ShareBasedCompensationNumberOfStockOptionPlans	3	item
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85973000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89027000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-98840000	USD
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74967000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63329000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87288000	shares
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5750000	USD
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74967000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63329000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87288000	shares
CY2013Q4	rigl	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2000	USD
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2013Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	12	item
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33484000	USD
CY2012Q4	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	298241000	USD
CY2013Q4	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	211975000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20854000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	191121000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	264757000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	273972000	USD
CY2013Q4	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	202674000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	135000	USD
CY2013Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	17000	USD
CY2013Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	181846000	USD
CY2013Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue	20875000	USD
CY2013	rigl	Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod	P159D
CY2013	rigl	Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than This Period AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThanThisPeriod	P1Y
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	31255000	USD
CY2013Q4	rigl	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	17000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26839000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26062000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22384000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20236000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4455000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5826000	USD
CY2013	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	445000	USD
CY2012	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	422000	USD
CY2012	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment	417000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2592000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2433000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1955000	USD
CY2013Q4	rigl	Operating Leases Number Of Additional Periods Under Renewal Option OperatingLeasesNumberOfAdditionalPeriodsUnderRenewalOption	2	item
CY2013	rigl	Operating Leases Additional Period Under Renewal Option OperatingLeasesAdditionalPeriodUnderRenewalOption	P5Y
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	14351000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	14929000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	15530000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	16153000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1351000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	62314000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14800000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14700000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14800000	USD
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	4	item
CY2013Q4	rigl	Unrecognized Tax Benefits That Would Impact Other Tax Accounts Including Deferred Taxes UnrecognizedTaxBenefitsThatWouldImpactOtherTaxAccountsIncludingDeferredTaxes	3900000	USD
CY2013Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	30	item
CY2013Q3	us-gaap	Restructuring Charges RestructuringCharges	1700000	USD
CY2013Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	1500000	USD
CY2013Q4	us-gaap	Supplemental Unemployment Benefits Continuation Of Health Care SupplementalUnemploymentBenefitsContinuationOfHealthCare	47000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	208772000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	236737000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	28869000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	24538000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3466000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	294109000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	294109000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23118000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	27420000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4145000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	283268000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	283268000	USD
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.336	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.475	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.021	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.039	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.379	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	51700000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10800000	USD
CY2012Q4	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included DeferredTaxAssetsOperatingLossCarryforwardsNotIncluded	1700000	USD
CY2013	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included Effect On Equity If Realized DeferredTaxAssetsOperatingLossCarryforwardsNotIncludedEffectOnEquityIfRealized	1700000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4300000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5001000	USD
CY2013Q4	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included DeferredTaxAssetsOperatingLossCarryforwardsNotIncluded	1700000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2600000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	750000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23174000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	1500000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24738000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71458000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71636000	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85274000	shares
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25456000	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25472000	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	1400000	USD
CY2013Q4	us-gaap	Contracts Revenue ContractsRevenue	5750000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25574000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22768000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23824000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16861000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87141000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87147000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87430000	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87430000	shares
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2011	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2460000	USD
CY2013	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	-536000	USD
CY2012	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	57000	USD
CY2011	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	-1384000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7166000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12617000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13168000	USD
CY2013Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.18	pure
CY2013	rigl	Share Based Compensation Arrangement By Share Based Payment Award Exercise Period Of Vested Options For Terminated Employees Excluding Employee Covered Under Restructuring ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePeriodOfVestedOptionsForTerminatedEmployeesExcludingEmployeeCoveredUnderRestructuring	P90D
CY2013	rigl	Number Of Terminated Employees Whose Vesting Period For Unvested Stock Option Accelerated NumberOfTerminatedEmployeesWhoseVestingPeriodForUnvestedStockOptionAccelerated	1	item
CY2013	rigl	Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Homogenous Groups For Determining Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfHomogenousGroupsForDeterminingFairValue	3	item
CY2013	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment	445000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
CY2013Q2	dei	Entity Public Float EntityPublicFloat	290854625	USD
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87524349	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87140632	shares
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	7166000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1867000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1624000	USD
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87140632	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87524349	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87524349	shares
CY2013	us-gaap	Contracts Revenue ContractsRevenue	7150000	USD
CY2012	us-gaap	Contracts Revenue ContractsRevenue	2250000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	4750000	USD
CY2013	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	75328000	USD
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	78778000	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69350000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19612000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22849000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21768000	USD
CY2013	us-gaap	Restructuring Charges RestructuringCharges	1679000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	96619000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	101627000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	91118000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-89469000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-99377000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-86368000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	442000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	537000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	420000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.02
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.36
CY2011	us-gaap	Interest Expense InterestExpense	25000	USD
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63329000	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	74967000	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87288000	shares
CY2013	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-35000	USD
CY2012	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	76000	USD
CY2011	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	44000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89062000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98764000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85929000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	236149000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	166131000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140505000	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	135729000	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2274000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3365000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1051000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	13168000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	12617000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-231000	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-232000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-244000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2206000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	141000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	153000	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3926000	USD
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-496000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142779000	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-196000	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	438000	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-402000	USD
CY2013	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-688000	USD
CY2012	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-150000	USD
CY2011	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	366000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-86061000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-85192000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69375000	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	308846000	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	475398000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	476038000	USD
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	365968000	USD
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	439724000	USD
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	415493000	USD
CY2013	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16479000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1221000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3377000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2303000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	72380000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-39051000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-62848000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1051000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139094000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	800000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1051000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	139094000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	141979000	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-12630000	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	14851000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	9756000	USD
CY2011	us-gaap	Interest Paid InterestPaid	21000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18633000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8877000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5750000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	8.00
CY2012	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	9.50
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	2500000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Financial statement preparation</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made by management include those relating to the terms of our research and development collaborations (i.e. revenue recognition of upfront fees and certain contingent payments), investments, stock-based compensation, impairment issues, estimated useful life of assets, estimated accruals, particularly research and development accruals, and potential loss contingencies. We believe that the estimates and judgments upon which we rely are reasonable based upon information available to us at the time that these estimates and judgments are made, however actual results could differ from these estimates. To the extent there are material differences between these estimates and actual results, our financial statements will be affected.</font></p> </div>
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentration of credit risk</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Financial instruments that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and available-for-sale securities. Cash equivalents and available-for-sale securities primarily consist of money market funds, U. S. treasury bills, government-sponsored enterprise securities, and corporate bonds and commercial paper. Due to the short-term nature of these investments, we believe we do not have a material exposure to credit risk arising from our investments. All cash and cash equivalents and available-for-sale securities are maintained with financial institutions that management believes are creditworthy.</font></p> </div>
CY2013Q4	rigl	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	499000	USD
CY2013Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16500000	USD
CY2012Q4	rigl	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	19813000	USD
CY2012	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	-0.114	pure
CY2011	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	0.000	pure
CY2013	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	0.000	pure
CY2012Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	0	item

Files In Submission

Name	View Source	Status
0001047469-14-001756-index-headers.html	Edgar Link	pending
0001047469-14-001756-index.html	Edgar Link	pending
0001047469-14-001756.txt	Edgar Link	pending
0001047469-14-001756-xbrl.zip	Edgar Link	pending
a2218507z10-k.htm	Edgar Link	pending
a2218507zex-23_1.htm	Edgar Link	pending
a2218507zex-31_1.htm	Edgar Link	pending
a2218507zex-31_2.htm	Edgar Link	pending
a2218507zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g194047.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20131231.xml	Edgar Link	completed
rigl-20131231.xsd	Edgar Link	pending
rigl-20131231_cal.xml	Edgar Link	unprocessable
rigl-20131231_def.xml	Edgar Link	unprocessable
rigl-20131231_lab.xml	Edgar Link	unprocessable
rigl-20131231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

2014 Q1 Form 10-K Financial Statement

#000104746914001756 Filed on March 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL RIGEL PHARMACEUTICALS INC Stock $rigl

2014 Q1 Form 10-K Financial Statement

#000104746914001756 Filed on March 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl